HK1253347A1 - IL-2Rβ選擇性激動劑和長效IL-15激動劑的組合 - Google Patents
IL-2Rβ選擇性激動劑和長效IL-15激動劑的組合Info
- Publication number
- HK1253347A1 HK1253347A1 HK18112641.8A HK18112641A HK1253347A1 HK 1253347 A1 HK1253347 A1 HK 1253347A1 HK 18112641 A HK18112641 A HK 18112641A HK 1253347 A1 HK1253347 A1 HK 1253347A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- agonist
- 2rbeta
- acting
- combination
- long
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562239207P | 2015-10-08 | 2015-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1253347A1 true HK1253347A1 (zh) | 2019-06-14 |
Family
ID=57249859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18112641.8A HK1253347A1 (zh) | 2015-10-08 | 2018-10-03 | IL-2Rβ選擇性激動劑和長效IL-15激動劑的組合 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180296645A1 (zh) |
| EP (1) | EP3359182B1 (zh) |
| JP (3) | JP7407511B2 (zh) |
| KR (1) | KR20180063184A (zh) |
| CN (1) | CN108135978A (zh) |
| AU (1) | AU2016335860B2 (zh) |
| CA (1) | CA3000211A1 (zh) |
| HK (1) | HK1253347A1 (zh) |
| IL (1) | IL258456B (zh) |
| MA (1) | MA47290A (zh) |
| MX (1) | MX2018004296A (zh) |
| WO (1) | WO2017062832A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3060410A1 (en) * | 2017-05-15 | 2018-11-22 | Nektar Therapeutics | Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods |
| US11248025B2 (en) | 2019-06-03 | 2022-02-15 | Medikine, Inc. | IL-2alpha receptor subunit binding compounds |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077519A (en) * | 1993-01-29 | 2000-06-20 | University Of Pittsburgh | Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients |
| EP0728210B1 (en) * | 1993-11-12 | 2005-04-13 | Gilead Sciences, Inc. | Thrombin mutants |
| US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
| JP4560629B2 (ja) * | 2005-03-31 | 2010-10-13 | 国立大学法人 筑波大学 | 腫瘍壊死誘導療法の抗腫瘍効果増強剤 |
| US20060257361A1 (en) * | 2005-04-12 | 2006-11-16 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Novel form of interleukin-15, Fc-IL-15, and methods of use |
| EP1896082B1 (en) | 2005-06-16 | 2012-12-26 | Nektar Therapeutics | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
| RU2399382C2 (ru) * | 2005-12-21 | 2010-09-20 | Сентоклон Аб | Улучшенный способ увеличения числа опухоле-реактивных т-лимфоцитов в иммунотерапии онкологических больных |
| KR101442867B1 (ko) * | 2006-12-27 | 2014-09-25 | 넥타르 테라퓨틱스 | 제거될 수 있는 결합을 지니는 인자 ⅸ 부분중합체 컨주게이트 |
| WO2009135031A1 (en) * | 2008-04-30 | 2009-11-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Substituted il-15 |
| HUE054318T2 (hu) * | 2010-11-12 | 2021-08-30 | Nektar Therapeutics | IL-2 molekularész konjugátumai és polimer |
| CN106132438B (zh) * | 2014-02-21 | 2020-03-03 | 尼克塔治疗印度私人有限公司 | 与抗CTLA-4抗体或抗PD-1抗体组合的IL-2Rβ选择性激动剂 |
| MA39711A (fr) * | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
-
2016
- 2016-10-07 EP EP16791713.7A patent/EP3359182B1/en active Active
- 2016-10-07 CN CN201680058497.XA patent/CN108135978A/zh active Pending
- 2016-10-07 JP JP2018517898A patent/JP7407511B2/ja active Active
- 2016-10-07 KR KR1020187011922A patent/KR20180063184A/ko not_active Application Discontinuation
- 2016-10-07 CA CA3000211A patent/CA3000211A1/en active Pending
- 2016-10-07 WO PCT/US2016/056088 patent/WO2017062832A1/en active Application Filing
- 2016-10-07 US US15/765,207 patent/US20180296645A1/en active Pending
- 2016-10-07 MX MX2018004296A patent/MX2018004296A/es unknown
- 2016-10-07 AU AU2016335860A patent/AU2016335860B2/en active Active
- 2016-10-07 MA MA047290A patent/MA47290A/fr unknown
-
2018
- 2018-03-29 IL IL258456A patent/IL258456B/en unknown
- 2018-10-03 HK HK18112641.8A patent/HK1253347A1/zh unknown
-
2021
- 2021-02-04 JP JP2021016606A patent/JP2021066748A/ja not_active Withdrawn
-
2023
- 2023-05-24 JP JP2023085387A patent/JP2023099731A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021066748A (ja) | 2021-04-30 |
| EP3359182B1 (en) | 2023-04-19 |
| IL258456A (en) | 2018-06-28 |
| JP2023099731A (ja) | 2023-07-13 |
| KR20180063184A (ko) | 2018-06-11 |
| IL258456B (en) | 2021-07-29 |
| CA3000211A1 (en) | 2017-04-13 |
| JP7407511B2 (ja) | 2024-01-04 |
| MA47290A (fr) | 2019-11-27 |
| US20180296645A1 (en) | 2018-10-18 |
| JP2018530568A (ja) | 2018-10-18 |
| AU2016335860B2 (en) | 2023-08-10 |
| EP3359182A1 (en) | 2018-08-15 |
| CN108135978A (zh) | 2018-06-08 |
| WO2017062832A1 (en) | 2017-04-13 |
| AU2016335860A1 (en) | 2018-04-12 |
| MX2018004296A (es) | 2018-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2558787B (en) | Management of moving objects | |
| EP3234794A4 (en) | Gallery of messages with a shared interest | |
| GB201514756D0 (en) | Compound and method of use | |
| HK1245369A1 (zh) | 錨固件 | |
| HK1248215A1 (zh) | 麥角靈化合物及其用途 | |
| HK1250146A1 (zh) | 抗前-bcr拮抗劑和方法 | |
| HK1253347A1 (zh) | IL-2Rβ選擇性激動劑和長效IL-15激動劑的組合 | |
| SG11201607624VA (en) | Anchor | |
| HK1219523A1 (zh) | 抗震裝置 | |
| PL3274596T3 (pl) | Kotwa rozporowa | |
| GB201514981D0 (en) | Analysing effects of programs on mobile devices | |
| HK1251029A1 (zh) | 觸覺的端徑跳測量和長度測量 | |
| GB201511512D0 (en) | Use of cell-free nucleosomes as biomarkers | |
| GB2526567B (en) | Anchor | |
| GB201417529D0 (en) | Beta lactamase inhibitors | |
| GB201415250D0 (en) | Compound and method | |
| GB201403802D0 (en) | An insulation member | |
| EP3185901C0 (en) | COMPOUND AND METHOD | |
| PL3120032T3 (pl) | Kotwa z metalu | |
| GB201417379D0 (en) | Comparator | |
| GB2529715B (en) | Assembly mount and method | |
| GB201400932D0 (en) | Location of criticality | |
| GB201501010D0 (en) | An item of wootwear | |
| GB2530519B (en) | Centralizer and Associated Devices | |
| GB2529697B (en) | Centralizer and associated devices |